Pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for advanced non-squamous non-small cell lung cancer (NSCLC)

IF 42.1 1区医学 Q1 ONCOLOGY

Journal of Clinical Oncology Pub Date : 2008-05-20 DOI:10.1200/JCO.2008.26.15_SUPPL.8044

J. Patel, T. Hensing, F. Rademaker, E. Hart, C. Obasaju, J. Treat, D. Milton, P. Bonomi

{"title":"Pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for advanced non-squamous non-small cell lung cancer (NSCLC)","authors":"J. Patel, T. Hensing, F. Rademaker, E. Hart, C. Obasaju, J. Treat, D. Milton, P. Bonomi","doi":"10.1200/JCO.2008.26.15_SUPPL.8044","DOIUrl":null,"url":null,"abstract":"8044 Background: Pemetrexed in combination with carboplatin has been shown to have promising activity, particularily in adenocarcinoma and large cell carcinoma, as well as superior toxicity profile in advanced NSCLC. Bevacizumab has been shown to improve survival of patients with advanced NSCLC when combined with other platin doublets. This study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab was designed to evaluate toxicities and estimate median time to progression of this novel regimen. Methods: Pts must be chemotherapy naive, stage IIIB (effusion) or IV non-squamous NSCLC, PS 0–1, and have no evidence of CNS metastases. Patients receive pemetrexed 500 mg/m2, carboplatin AUC 6, and bevacizumab 15 mg/kg. Treatment is repeated every 21 days for 6 cycles. For patients with SD or PR, pemetrexed 500 mg/m2 and bevacizumab 15 mg/kg are continued every 21 days until disease progression or toxicity. All patients receive folic acid, vitamin B12 and steroid prophylaxis....","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":"26 1","pages":"8044-8044"},"PeriodicalIF":42.1000,"publicationDate":"2008-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"15","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1200/JCO.2008.26.15_SUPPL.8044","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 15

Abstract

8044 Background: Pemetrexed in combination with carboplatin has been shown to have promising activity, particularily in adenocarcinoma and large cell carcinoma, as well as superior toxicity profile in advanced NSCLC. Bevacizumab has been shown to improve survival of patients with advanced NSCLC when combined with other platin doublets. This study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab was designed to evaluate toxicities and estimate median time to progression of this novel regimen. Methods: Pts must be chemotherapy naive, stage IIIB (effusion) or IV non-squamous NSCLC, PS 0–1, and have no evidence of CNS metastases. Patients receive pemetrexed 500 mg/m2, carboplatin AUC 6, and bevacizumab 15 mg/kg. Treatment is repeated every 21 days for 6 cycles. For patients with SD or PR, pemetrexed 500 mg/m2 and bevacizumab 15 mg/kg are continued every 21 days until disease progression or toxicity. All patients receive folic acid, vitamin B12 and steroid prophylaxis....

查看原文本刊更多论文

培美曲塞和卡铂联合贝伐单抗维持培美曲塞和贝伐单抗作为晚期非鳞状非小细胞肺癌(NSCLC)的一线治疗

8044背景:培美曲塞联合卡铂已被证明具有良好的活性，特别是在腺癌和大细胞癌中，并且在晚期非小细胞肺癌中具有优越的毒性。贝伐单抗与其他铂双药联合使用可提高晚期NSCLC患者的生存率。这项培美曲塞和卡铂联合贝伐单抗与培美曲塞和贝伐单抗维持的研究旨在评估这种新方案的毒性和估计中位进展时间。方法:患者必须是首次化疗，IIIB期(积液)或IV期非鳞状NSCLC, PS 0-1，无中枢神经系统转移的证据。患者接受培美曲塞500 mg/m2、卡铂AUC 6和贝伐单抗15 mg/kg的治疗。每21天重复治疗6个周期。对于SD或PR患者，培美曲塞500 mg/m2和贝伐单抗15 mg/kg每21天继续治疗，直到疾病进展或出现毒性。所有患者均接受叶酸、维生素B12和类固醇预防治疗....

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Clinical Oncology 医学-肿瘤学

CiteScore

41.20

自引率

2.20%

发文量

8215

审稿时长

2 months

期刊介绍： The Journal of Clinical Oncology serves its readers as the single most credible, authoritative resource for disseminating significant clinical oncology research. In print and in electronic format, JCO strives to publish the highest quality articles dedicated to clinical research. Original Reports remain the focus of JCO, but this scientific communication is enhanced by appropriately selected Editorials, Commentaries, Reviews, and other work that relate to the care of patients with cancer.